You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
隆平高科(000998.SZ)子公司隆平生物擬獲增資4000萬元
格隆匯 02-05 20:27

格隆匯2月5日丨隆平高科(000998.SZ)公佈,公司全資子公司隆平生物技術(海南)有限公司(“隆平生物”)成立於2019年5月10日,註冊資本1000萬元。為滿足隆平生物的研發活動需要,同時為激勵其核心團隊,隆平生物擬進行增資擴股。2020年2月4日,公司決策委員會2020年第一次(臨時)會議審議通過了《關於隆平生物技術(海南)有限公司增資擴股的議案》,同意隆平生物增資擴股方案,其中公司擬以自有資金新增認繳出資2125萬元,隆平生物員工成立的合夥企業認繳出資1000萬元,隆平生物核心團隊成立的合夥企業認繳出資875萬元。此次增資完成後,隆平生物的註冊資本由1000萬元變更為5000萬元。

隆平生物主營業務為生物工程技術開發、技術諮詢、技術交流、技術轉讓、技術推廣、技術服務,生物學研究服務,生物科學技術研究服務,現已打造了一支優秀轉基因性狀開發團隊,並已開發出抗性表現優良的轉基因產品。

此次交易將保障隆平生物的性狀研發項目按照既定規劃穩步開展,有利於推進公司的生物技術戰略,強化和完善公司的轉基因性狀產品儲備,提升公司在生物技術領域的競爭能力。

此次交易完成後,隆平生物仍為公司的控股子公司,不會導致公司失去對隆平生物的控制權,不會對公司未來財務狀況及經營成果產生不利影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account